VJOncology Podcast

Latest Episodes:

The GI Cancer Sessions: Highlights from ASCO 2021 Oct 07, 2021

Show notes

At the virtual 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, important advances and potentially practice-changing trial data were presented in a range of gastrointestinal (GI) malignancies such as esophageal, gastric and colorectal cancer. VJOncology has assembled an esteemed panel of leading GI experts to discuss the latest exciting developments, what these advances could actually mean for clinical practice in the future and what still needs to be done.

Tobias Arkenau, MD, PHD, Sarah Cannon Research Institute UK, London, UK, chairs this roundtable discussion and is joined by:

Deborah Mukherji, MBBS, FRCP, American University of Beirut Medical Center, Beirut, Lebanon
Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK
Lizzy Smyth, MD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Nataliya Uboha, MD, PhD, University of Wisconsin, Madison, WI
Susanna Ulahannan, MD, MMEd, University of Oklahoma, Oklahoma City, OK.

In this GI Cancer Session podcast, you will learn about the results of the CheckMate 648 and RATIONALE 302 trials in esophageal cancer, as well as key gastric cancer studies, including KEYNOTE-811 and MAHOGANY. The panel also offer their perspectives on the study of first-line FOLFOXIRI plus cetuximab or bevacizumab in patients with RAS wild-type metastatic colorectal cancer in the DEEPER trial, and colorectal cancer maintenance therapy in the PanaMa and FOCUS4 trials. The panel also consider the use of Nal-IRI in biliary tract and pancreatic cancers, as well as promising data on emerging therapies such as trastuzumab deruxtecan, an anti-HER2 antibody-drug-conjugate, in metastatic colorectal cancer from the DESTINY-CRC01 trial.

The post The GI Cancer Sessions: Highlights from ASCO 2021 appeared first on VJOncology.

Key clinical trial data in urothelial carcinoma at ASCO 2021 Sep 10, 2021

Show notes

Chemotherapy is central to the treatment of advanced or metastatic urothelial carcinoma (UC), and platinum-based treatments, like cisplatin, have been the first-line treatment options for many years. To address the limitations of platinum-based chemotherapeutics, additional therapeutics have become available in more recent years for first- and second-line use. Specifically, for patients who are cisplatin-ineligible or those who relapse, immune checkpoint inhibitors, such as avelumab, pembrolizumab, and atezolizumab, targeting the program cell death 1 protein (PD-1) or its ligand (PD-L1), have gained FDA approval. Latest clinical trials have also combined immunotherapy drugs with novel therapies, like the antibody-drug conjugate enfortumab vedotin, to demonstrate high response rates; this has instigated further studies into comparison with platinum-based chemotherapeutics. Evidence of disruption to the fibroblast growth factor receptor (FGFR) signaling pathway in UC has also resulted in multiple studies investigating FGFR inhibitors, like rogaratinib, as a potential treatment option for patients with UC.

In this deep dive, American Society of Clinical Oncology (ASCO) 2021 presenters Petros Grivas, MD, PhD, University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, WA; Terence W. Friedlander, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; and Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, will be sharing their insights into the latest advancements in immunotherapy for advanced urothelial carcinoma. Our experts will present the latest data from the JAVELIN Bladder 100, EV-103, and FORT-2 trials.

The post Key clinical trial data in urothelial carcinoma at ASCO 2021 appeared first on VJOncology.

Prostate Cancer Highlights from ASCO 2021 with Pedro Barata Aug 23, 2021

Show notes

This year, at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021, experts came together virtually to present and discuss the latest findings in oncology.

In this podcast, Pedro Barata, MD, MSc Tulane University School of Medicine, New Orleans, LA, discusses highlights from the meeting. He focuses on the results from four Phase III trials assessing various therapies for the treatment of prostate cancer. Dr Barata begins with VISION (NCT03511664), examining the addition of lutetium-177 to standard of care treatment in progressive metastatic prostate cancer, followed by PEACE-1 (NCT01957436), investigating abiraterone and prednisone ± radiotherapy for hormone-naïve metastatic patients. He continues by highlighting Peace III (NCT02194842), a trial investigating enzalutamide and radium-223 combination therapy in asymptomatic or mildly symptomatic castration-resistance patients and concludes by talking about the SWOG S1216 study (NCT01809691), examining androgen deprivation therapy plus TAK-700 in patients with hormone-sensitive prostate cancer.

This interview took place at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021.

The post Prostate Cancer Highlights from ASCO 2021 with Pedro Barata appeared first on VJOncology.

The Breast Cancer Sessions: Highlights from ASCO 2021 Aug 18, 2021

Show notes

VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Giuseppe Curigliano, MD, University of Milan, Milan, Italy, Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Andrew Tutt, MBChB, PhD, The Institute of Cancer Research, London, UK, to examine the recent major breakthroughs in breast cancer and what they mean for clinical practice.

Tune in to hear the expert panel offer their perspectives on adjuvant olaparib and the results of the OlympiA trial, capecitabine in the ECOG study, the GeparNuevo trial which looked at adding durvalumab to chemotherapy in patients with TNBC, as well as first-line paclitaxel plus durvalumab for TNBC in the BEGONIA trial. The panel also discuss the latest data for CDK4/6 inhibitors, SERDs and BCL-2 inhibitors, the use of talazoparib in the neoadjuvant setting and much more.

The post The Breast Cancer Sessions: Highlights from ASCO 2021 appeared first on VJOncology.

The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO 2021 Aug 18, 2021

Show notes

During the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, an exciting array of advances in genitourinary (GU) cancer research were presented. VJOncology has brought together a panel of leading GU experts to consider and debate the latest developments in bladder and kidney cancer and offer their perspectives on how they could impact patient care in the future.

This post-ASCO GU cancer roundtable discussion is chaired by Elizabeth Plimack, MD, MS, from the Fox Chase Cancer Center, Philadelphia, PA, who is joined by Rana McKay, MD, University of California San Diego, San Diego, CA, and Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK.

Listen to this podcast to learn about the latest research in immunotherapy for the treatment of muscle-invasive bladder cancer and the exciting recent developments in bladder-sparing approaches. The panel also discuss groundbreaking adjuvant pembrolizumab data from KEYNOTE-564 in renal cell carcinoma (RCC) and how it will change their clinical practice in the future. In addition, we hear about updated results from the CLEAR trial, KEYNOTE-426, as well as alternative approaches in treating advanced RCC such as using the probiotic CBM588 in conjunction with immunotherapy.

The post The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO 2021 appeared first on VJOncology.

ASCO 2021: Immunotherapy updates in lung cancer Aug 04, 2021

Show notes

Various immunotherapies including checkpoint inhibitors have emerged as effective treatment options for patients with non-small cell lung cancer (NSCLC). Immune checkpoints proteins such as PD-1, PD-L1 and CTLA-4 have become potential targets, as they have an immunosuppressive function and are overexpressed in certain cancers. Several checkpoint inhibitors have already received FDA approval including nivolumab and ipilimumab, and ongoing research is being conduced to assess novel therapies and combination regimens.

In this podcast, Heather Wakelee, MD, Stanford University, Stanford, CA, David Spigel, MD, Sarah Cannon Research Institute, Nashville, TN, and Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL discuss results from the IMpower010 trial (NCT02486718), which assessed the anti-PD-L1 monoclonal antibody atezolizumab in non-small cell lung cancer (NSCLC), as well as the PACIFIC trial (NCT02125461), which investigated durvalumab in unresectable stage III NSCLC. The evolving field of checkpoint inhibitors in NSCLC and combining checkpoint inhibitors with cell therapies are also discussed. This interview took place at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021.

The post ASCO 2021: Immunotherapy updates in lung cancer appeared first on VJOncology.

EAU 2021: updates in testicular cancer Jul 28, 2021

Show notes

Whilst advances in diagnostic procedures, radiotherapies, cisplatin-based chemotherapy, and surgery have meant that testicular cancer is curable in around 95% of cases, the side effects of radiotherapy and chemotherapy can significantly impact quality-of-life (QoL) outcomes for patients treated for testicular cancer in both the short and long term. Currently, much research is investigating how novel approaches to treatment and monitoring can be used and incorporated to improve QoL outcomes for patients treated for testicular cancer.

In this podcast, Tahlita Zuiverloon, MD, PhD, of the Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Peter Albers, MD, University of Düsseldorf, Düsseldorf, Germany; and Matthew Murray, MB, BChir, PhD, Cambridge University Hospitals NHS Foundation Trust, discuss key updates in the field of testicular cancer, as presented at the 2021 European Association of Urology (EAU) Virtual Meeting, including research on the use of MRI versus CT, surgery in metastatic disease and microRNA biomarkers.

The post EAU 2021: updates in testicular cancer appeared first on VJOncology.

Highlights from ESMO WCGIC 2021: VALENTINO, KEYNOTE-811 & BEACON-CRC Jul 15, 2021

Show notes

The ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2021 annual meeting took place virtually this year and leading experts came together to present on the most recent developments in GI cancer.

In this podcast, Paolo Manca, MD, Istituto Nazionale dei Tumori Milano, Milano, Italy, Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, and Dan Aderka, MD, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel, discuss results from the VALENTINO (NCT02476045), KEYNOTE-811 (NCT03615326), and BEACON-CRC (NCT02928224) trials. Both the VALENTINO and KEYNOTE-811 trials investigated the use of monoclonal antibodies with chemotherapy in colorectal and gastric cancer respectively, whereas the BEACON-CRC trial assessed the effects of first-line bevacizumab in BRAF V600E-mutant metastatic colorectal cancer.

This interview took place at the virtual ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2021 annual meeting.

The post Highlights from ESMO WCGIC 2021: VALENTINO, KEYNOTE-811 & BEACON-CRC appeared first on VJOncology.

What’s new? Treating breast cancer with brain metastases Jul 13, 2021

Show notes

Metastatic breast cancer is breast cancer that has spread to other regions of the body, most commonly the liver, brain, bones, or lungs. Although significant developments have been made in the treatment options available for patients with metastatic breast cancer, the occurrence of brain metastases remains a substantial clinical challenge.

The incidence and prognosis of patients with brain metastases related to breast cancer varies by subtype. Triple negative disease has the highest rates, occurring in as many as 46% of cancers, compared to 35% and 14% in HER2-positive and hormone receptor (HR)-positive disease, respectfully. Brain metastases are not only associated with poor prognosis, but can also cause neurological defects, through their effect on the cognitive and sensory functions of the brain. Ongoing research into the biology of metastases and increasing clinical trial inclusion are paving the way for discovery of new treatment strategies to achieve long-lasting efficacy against brain metastases.

In this exclusive podcast, Erika Hamilton, of the Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN; Guy Jerusalem of the University of Liège, Belgium; Erica Michelle Stringer-Reasor, of the University of Alabama at Birmingham, AL; and Gaio Griguolo, of the Veneto Institute of Oncology, Padova, Italy, discuss the latest updates in metastatic breast cancer treatment.

The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

The post What’s new? Treating breast cancer with brain metastases appeared first on VJOncology.

Global breast cancer care Jul 13, 2021

Show notes

Healthcare systems around the world differ in financial and political situations. Therefore, it is vital to implement a global outlook of breast cancer care that focuses on applying access to high-quality practices, especially in low- and middle-income countries, where breast cancer remains a public health crisis.

During this podcast, Andre Ilbawi, MD, of the World Health Organization (WHO), Carol Benn, MBBCh, FCS, of the Breast Care Center of Excellence, Milpark Hospital in Johannesburg, South Africa, and Cynthia Villareal-Garza, MD, DSc, of the Mexican National Cancer Institute & Tecnologico de Monterrey, Mexico discuss the latest information on global breast cancer care and specific practices within South Africa and Mexico.

The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

The post Global breast cancer care appeared first on VJOncology.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected